Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Roeker, L.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C. S.; Lewis, D. J.; Gerson, J. N.; Alencar, A.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Chen, J.; Nair, B.; Tsai, D. E.; Ku, N. C.; Davids, M. S.; Brown, J. R.; Jurczak, W.; Mato, A. R. |
| Abstract Title: | Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cll; btk inhibitor; bruin; non-covalent |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S315 |
| End Page: | S316 |
| Language: | English |
| ACCESSION: | WOS:000691910500184 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01746-8 |
| Notes: | Meeting Abstract: CLL-039 -- Source: Wos |
